Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Penile Neoplasms 1Oropharyngeal Neoplasms 1Melanoma 1Anus Neoplasms 1

Interventions

Cisplatin 7pembrolizumab 4Radiotherapy 3Paclitaxel 3fludarabine 2durvalumab 2aldesleukin 2Taxes 2Fluorouracil 2Cyclophosphamide 2Biopsy 2veliparib 1tremelimumab 1prednylidene 1niraparib 1fludarabine phosphate 1exifone 1entinostat 1dostarlimab 1deltacortene 1dehydroftorafur 1bintrafusp alfa protein, human 1advexin 1Tomography, X-Ray Computed 1Specimen Handling 1Radiosurgery 1Radiation 1Prednisone 1Platinum 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Oropharyngeal Neoplasms × Adoptive Transfer × Clear all
NCT05639972 2026-02-27

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Rutgers, The State University of New Jersey

Phase 1/2 Recruiting
15 enrolled
GastrointestinalGenitourinaryGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡